Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15774511 | 0.93 | CYP2C19 (0.38) | CYP2C19ALDH1A1SMN1; SMN2TSHRUSP2 | |
| SCHEMBL4450788 | 0.87 | CYP2C19 (0.32) | CYP2C19ALDH1A1USP2LMNACYP1A2 | |
| SCHEMBL8914159 | 0.84 | CYP2C19 (0.68) | CYP2C19ALDH1A1SMN1; SMN2TSHRUSP2 | |
| SCHEMBL17085549 | 0.82 | CYP2C19 (0.43) | CYP2C19ALDH1A1SMN1; SMN2TSHRUSP2 | |
| SCHEMBL20000117 | 0.81 | CYP2C19 (0.39) | CYP2C19ALDH1A1SMN1; SMN2TSHRUSP2 | |
| SCHEMBL27585847 | 0.81 | CYP2C19 (0.64) | CYP2C19ALDH1A1SMN1; SMN2TSHRUSP2 | |
| SCHEMBL11383842 | 0.79 | CYP2C19 (0.41) | CYP2C19ALDH1A1SMN1; SMN2TSHRUSP2 | |
| SCHEMBL5132557 | 0.78 | ALDH1A1 (0.45) | CYP2C19ALDH1A1SMN1; SMN2TSHRUSP2 | |
| SCHEMBL6136974 | 0.78 | CYP2C19 (0.43) | CYP2C19ALDH1A1SMN1; SMN2TSHRUSP2 | |
| SCHEMBL10822133 | 0.77 | CYP2C19 (0.39) | CYP2C19ALDH1A1SMN1; SMN2TSHRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298781-A1 | COMPOUNDS FOR THE INHIBITION OF APOPTOSIS | CONSEJO SUPERIOR DE (ES) | 2009-12-03 | — | — | US | disclosed |
| CN-1326519-C | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2007-07-18 | — | — | CN | disclosed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298781-A1 | COMPOUNDS FOR THE INHIBITION OF APOPTOSIS | BAX, BCL2, CASP3 | CYP2C19 2889/4885ALDH1A1 1468/4885SMN1; SMN2 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.